Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07519395 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)
A Phase 2 study, sponsored by GlaxoSmithKline.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 420
- Enrollment target
NCT07519395 is a Phase 2 study that is actively recruiting participants, run by GlaxoSmithKline. The registered enrollment target is 420 participants.
The verdict
NCT07519395, a Phase 2 study, is actively recruiting participants, sponsored by GlaxoSmithKline.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 420 participants
- Enrollment target
Study Summary
This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts. After the first part, some participants will be randomly chosen again to either get a higher dose or stop the drug.
Interventions
- DRUG Placebo
- DRUG Camlipixant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 420 participants |
| Start Date | 2026-04-08 |
| Est. Completion | 2027-07-13 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07519395
The ClinicalTrials.gov registry entry for NCT07519395 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is GlaxoSmithKline, which has 1,345 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07519395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07519395 about?
NCT07519395 is a clinical study titled "A Study to Investigate Abdominal Symptoms With Camlipixant Compared With Placebo in Adults With Irritable Bowel Syndrome - Diarrhea (IBS-D) and Irritable Bowel Syndrome - Mixed (IBS-M)". This study is designed to evaluate the efficacy and safety of camlipixant in adults with IBS-D and IBS-M. The study has two parts. After the first part, some participants will be randomly chosen again to either get a higher dose or stop the drug.
What is the current status of trial NCT07519395?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2026-04-08. Estimated completion is 2027-07-13.
What interventions are being tested in trial NCT07519395?
The interventions under investigation include: Placebo (DRUG), Camlipixant (DRUG).
Who is sponsoring clinical trial NCT07519395?
This trial is sponsored by GlaxoSmithKline, which has 1,345 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.